• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Pursuit of New Treatments for Focal Segmental Glomerulosclerosis: Harmonizing Innovation With the DUET Study of Sparsentan.

作者信息

Mishra Aparajita, Itoku Ai, Reidy Kimberly, Kaskel Frederick

机构信息

Division of Pediatric Nephrology, Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, New York.

出版信息

Kidney Med. 2024 May 22;6(6):100844. doi: 10.1016/j.xkme.2024.100844. eCollection 2024 Jun.

DOI:10.1016/j.xkme.2024.100844
PMID:38840848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11151161/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f1/11151161/0d8edc67757d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f1/11151161/0d8edc67757d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f1/11151161/0d8edc67757d/gr1.jpg

相似文献

1
The Pursuit of New Treatments for Focal Segmental Glomerulosclerosis: Harmonizing Innovation With the DUET Study of Sparsentan.局灶节段性肾小球硬化症新疗法的探索：将创新与司帕生坦的DUET研究相结合。
Kidney Med. 2024 May 22;6(6):100844. doi: 10.1016/j.xkme.2024.100844. eCollection 2024 Jun.
2
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.司帕生坦用于局灶节段性肾小球硬化症的DUET开放标签扩展研究：长期疗效和安全性
Kidney Med. 2024 Apr 26;6(6):100833. doi: 10.1016/j.xkme.2024.100833. eCollection 2024 Jun.
3
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.局灶节段性肾小球硬化症中任何时间完全蛋白尿缓解的意义：司帕生坦DUET试验
Kidney Int Rep. 2023 Aug 4;8(10):2017-2028. doi: 10.1016/j.ekir.2023.07.022. eCollection 2023 Oct.
4
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).司帕生坦与厄贝沙坦治疗原发性局灶节段性肾小球硬化症患者的疗效与安全性比较：随机对照试验设计（DUET）
Kidney Int Rep. 2017 Mar 4;2(4):654-664. doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul.
5
Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist.斯巴森坦：首个双重内皮素和血管紧张素 II 受体拮抗剂。
Ann Pharmacother. 2024 Jun;58(6):645-656. doi: 10.1177/10600280231198925. Epub 2023 Sep 14.
6
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.局灶节段性肾小球硬化患者的3期司帕生坦对比厄贝沙坦（DUPLEX）研究的研究设计
Kidney Int Rep. 2020 Jan 8;5(4):494-502. doi: 10.1016/j.ekir.2019.12.017. eCollection 2020 Apr.
7
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.司帕生坦与厄贝沙坦治疗局灶节段性肾小球硬化症的比较
N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3.
8
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis.健康志愿者和局灶节段性肾小球硬化症患者中 sparsentan 的群体药代动力学分析。
CPT Pharmacometrics Syst Pharmacol. 2023 Aug;12(8):1080-1092. doi: 10.1002/psp4.12996. Epub 2023 Jun 1.
9
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.司帕生坦3期双盲研究中局灶节段性肾小球硬化症患者的基线特征
Kidney Int Rep. 2024 Jan 28;9(4):1020-1030. doi: 10.1016/j.ekir.2024.01.032. eCollection 2024 Apr.
10
Sparsentan: First Approval.斯巴森坦：首次批准。
Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.

引用本文的文献

1
The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives.B淋巴细胞亚群在肾病综合征中的作用：功能、机制、临床意义及未来展望。
Front Immunol. 2025 Aug 7;16:1598197. doi: 10.3389/fimmu.2025.1598197. eCollection 2025.

本文引用的文献

1
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.司帕生坦用于局灶节段性肾小球硬化症的DUET开放标签扩展研究：长期疗效和安全性
Kidney Med. 2024 Apr 26;6(6):100833. doi: 10.1016/j.xkme.2024.100833. eCollection 2024 Jun.
2
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today.肾小球疾病中 NEPTUNE 匹配研究网络（NEPTUNE）的原理和设计：今天，为合适的患者设计合适的试验。
Kidney Int. 2024 Feb;105(2):218-230. doi: 10.1016/j.kint.2023.11.018.
3
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
司帕生坦与厄贝沙坦治疗局灶节段性肾小球硬化症的比较
N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3.
4
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.局灶节段性肾小球硬化症中任何时间完全蛋白尿缓解的意义：司帕生坦DUET试验
Kidney Int Rep. 2023 Aug 4;8(10):2017-2028. doi: 10.1016/j.ekir.2023.07.022. eCollection 2023 Oct.
5
Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis.新型治疗模式：局灶节段性肾小球硬化症
Kidney Int Rep. 2022 Oct 8;8(1):30-35. doi: 10.1016/j.ekir.2022.10.004. eCollection 2023 Jan.
6
The first randomized controlled trial in pediatric nephrology: the history of the International Study of Kidney Disease in Children (ISKDC).儿科肾脏病学领域的首个随机对照试验：儿童肾脏病国际研究（ISKDC）的历史。
Pediatr Nephrol. 2023 Dec;38(12):3947-3954. doi: 10.1007/s00467-022-05838-1. Epub 2023 Jan 10.
7
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.国际儿科肾病学会关于儿童激素耐药型肾病综合征诊断和治疗的临床实践推荐意见。
Pediatr Nephrol. 2020 Aug;35(8):1529-1561. doi: 10.1007/s00467-020-04519-1. Epub 2020 May 7.
8
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.DUET 研究：一项评估 Sparsentan 在 FSGS 患者中的疗效和安全性的 2 期研究。
J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091.
9
Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat.在嘌呤霉素氨基核苷诱导的大鼠肾病模型中，内皮素-1 受体拮抗剂的减少蛋白尿作用。
Pediatr Res. 2018 May;83(5):1041-1048. doi: 10.1038/pr.2018.11. Epub 2018 Feb 21.
10
Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.肾素-血管紧张素-醛固酮系统与内皮素-1双重抑制治疗慢性肾脏病
Am J Physiol Regul Integr Comp Physiol. 2016 May 15;310(10):R877-84. doi: 10.1152/ajpregu.00425.2015. Epub 2016 Mar 23.